Cargando…
The role of interleukin-17 in asthma: a protective response?
While there now exist effective treatments for type 2 high, eosinophilic asthma, there are no specific therapies for 40–50% of people with asthma with other phenotypes, which result from poorly understood underlying pathological mechanisms. One such pathology is neutrophilic inflammation, which has...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248344/ https://www.ncbi.nlm.nih.gov/pubmed/32494573 http://dx.doi.org/10.1183/23120541.00364-2019 |
_version_ | 1783538351787212800 |
---|---|
author | Hynes, Gareth M. Hinks, Timothy S.C. |
author_facet | Hynes, Gareth M. Hinks, Timothy S.C. |
author_sort | Hynes, Gareth M. |
collection | PubMed |
description | While there now exist effective treatments for type 2 high, eosinophilic asthma, there are no specific therapies for 40–50% of people with asthma with other phenotypes, which result from poorly understood underlying pathological mechanisms. One such pathology is neutrophilic inflammation, which has been associated with interleukin (IL)-17 family cytokines. Human genetic studies identified IL-17 polymorphisms associated with asthma; in murine models of allergic airways disease, IL-17A contributes to airway hyperresponsiveness, and in humans, elevated airway IL-17A levels are repeatedly observed in severe asthma. However, the directionality of this association is unknown, and the assumption that IL-17 cytokines drive disease pathology remains speculative. Here, we explore the evidence underlying the relationship between IL-17 and asthma, we review lessons learned from investigating IL-17 in other inflammatory diseases, and discuss the possibility that IL-17 may even be protective in asthma rather than pathogenic. We also critically examine the newly proposed paradigm of a reciprocal relationship between type 2 and type 17 airways inflammation. In summary, we suggest an association between IL-17 and asthma, but research is needed examining the diverse functions of these cytokines, their longitudinal stability, their response to clinical interventions, and for mechanistic studies determining whether they are protective or pathogenic. |
format | Online Article Text |
id | pubmed-7248344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-72483442020-06-02 The role of interleukin-17 in asthma: a protective response? Hynes, Gareth M. Hinks, Timothy S.C. ERJ Open Res Reviews While there now exist effective treatments for type 2 high, eosinophilic asthma, there are no specific therapies for 40–50% of people with asthma with other phenotypes, which result from poorly understood underlying pathological mechanisms. One such pathology is neutrophilic inflammation, which has been associated with interleukin (IL)-17 family cytokines. Human genetic studies identified IL-17 polymorphisms associated with asthma; in murine models of allergic airways disease, IL-17A contributes to airway hyperresponsiveness, and in humans, elevated airway IL-17A levels are repeatedly observed in severe asthma. However, the directionality of this association is unknown, and the assumption that IL-17 cytokines drive disease pathology remains speculative. Here, we explore the evidence underlying the relationship between IL-17 and asthma, we review lessons learned from investigating IL-17 in other inflammatory diseases, and discuss the possibility that IL-17 may even be protective in asthma rather than pathogenic. We also critically examine the newly proposed paradigm of a reciprocal relationship between type 2 and type 17 airways inflammation. In summary, we suggest an association between IL-17 and asthma, but research is needed examining the diverse functions of these cytokines, their longitudinal stability, their response to clinical interventions, and for mechanistic studies determining whether they are protective or pathogenic. European Respiratory Society 2020-05-26 /pmc/articles/PMC7248344/ /pubmed/32494573 http://dx.doi.org/10.1183/23120541.00364-2019 Text en Copyright ©ERS 2020 http://creativecommons.org/licenses/by-nc/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Reviews Hynes, Gareth M. Hinks, Timothy S.C. The role of interleukin-17 in asthma: a protective response? |
title | The role of interleukin-17 in asthma: a protective response? |
title_full | The role of interleukin-17 in asthma: a protective response? |
title_fullStr | The role of interleukin-17 in asthma: a protective response? |
title_full_unstemmed | The role of interleukin-17 in asthma: a protective response? |
title_short | The role of interleukin-17 in asthma: a protective response? |
title_sort | role of interleukin-17 in asthma: a protective response? |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248344/ https://www.ncbi.nlm.nih.gov/pubmed/32494573 http://dx.doi.org/10.1183/23120541.00364-2019 |
work_keys_str_mv | AT hynesgarethm theroleofinterleukin17inasthmaaprotectiveresponse AT hinkstimothysc theroleofinterleukin17inasthmaaprotectiveresponse AT hynesgarethm roleofinterleukin17inasthmaaprotectiveresponse AT hinkstimothysc roleofinterleukin17inasthmaaprotectiveresponse |